CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. by Deng, Xinyu et al.
UCLA
UCLA Previously Published Works
Title



















eScholarship.org Powered by the California Digital Library
University of California
Oncotarget38294www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 24), pp: 38294-38308
CD24 Expression and differential resistance to chemotherapy in 
triple-negative breast cancer
Xinyu Deng1, Sophia Apple2,*, Hong Zhao1,3,*, Jeongyoon Song1,4,*, Minna Lee1, 
William Luo1, Xiancheng Wu1, Debra Chung1, Richard J. Pietras5, Helena R. Chang1
1Gonda, UCLA Breast Cancer Research Laboratory and Revlon, UCLA Breast Center, Department of Surgery, David Geffen School 
of Medicine, University of California, Los Angeles, CA 90095-7028, USA
2Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095-1732, USA
3Department of Breast Surgery, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, 
P. R. China
4Department of Surgery, East-West Medical Center, Kyung Hee University College of Medicine, Dongdaemun-gu, Seoul 02447, 
South Korea
5Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los 
Angeles, CA 90095-1678, USA
*These authors contributed equally to this work
Correspondence to: Helena R. Chang, email: hchang@mednet.ucla.edu
Keywords: breast cancer, CD24, drug resistance, EMT, chemotherapy
Received: August 11, 2016    Accepted: February 21, 2017    Published: March 15, 2017
Copyright: Xinyu Deng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC 
BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Breast cancer (BC) is a leading cause of cancer-related death in women. 
Adjuvant systemic chemotherapies are effective in reducing risks of recurrence and 
have contributed to reduced BC mortality. Although targeted adjuvant treatments 
determined by biomarkers for endocrine and HER2-directed therapies are largely 
successful, predicting clinical benefit from chemotherapy is more challenging. Drug 
resistance is a major reason for treatment failures. Efforts are ongoing to find 
biomarkers to select patients most likely to benefit from chemotherapy. Importantly, 
cell surface biomarkers CD44+/CD24– are linked to drug resistance in some reports, 
yet underlying mechanisms are largely unknown. This study focused on the potential 
role of CD24 expression in resistance to either docetaxel or doxorubicin in part by 
the use of triple-negative BC (TNBC) tissue microarrays. In vitro assays were also 
done to assess changes in CD24 expression and differential drug susceptibility 
after chemotherapy. Further, mouse tumor xenograft studies were done to confirm  
in vitro findings. Overall, the results show that patients with CD24-positive TNBC 
had significantly worse overall survival and disease-free survival after taxane-based 
treatment. Also, in vitro cell studies show that CD44+/CD24+/high cells are more 
resistant to docetaxel, while CD44+/CD24–/low cells are resistant to doxorubicin. 
Both in vitro and in vivo studies show that cells with CD24-knockdown are more 
sensitive to docetaxel, while CD24-overexpressing cells are more sensitive to 
doxorubicin. Further, mechanistic studies indicate that Bcl-2 and TGF-βR1 signaling 
via ATM-NDRG2 pathways regulate CD24. Hence, CD24 may be a biomarker to select 
chemotherapeutics and a target to overcome TNBC drug resistance.  
INTRODUCTION 
Breast cancer (BC) is a leading cause of cancer-
related death in women worldwide [1]. Despite recent 
advances in targeted BC treatment, adjuvant chemotherapy 
remains the mainstay to improve survival in high-risk 
BC patients [2, 3]. Resistance to chemotherapy is a 
key factor in treatment failure. Better understanding of 
drug resistance mechanisms is crucial to advance BC 
management. 
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Triple-negative breast cancer (TNBC) is a BC subtype 
defined by lack of estrogen and progesterone receptors 
and absence of HER2 amplification [4]. As compared 
with other BC subtypes, TNBC patients have significantly 
worse prognosis despite use of chemotherapy [5]. Since 
there are no currently-approved targeted treatments for 
TNBC, chemotherapy is a standard intervention, yet patients 
often suffer early disease recurrence and metastasis due to 
development of drug resistance. 
Cluster of differentiation 24 (CD24) is a small GPI-
linked membrane glycoprotein with glycosylation sites 
that bind P-selectin [6]. As an adhesion molecule, CD24 
is widely expressed in many cancer types, including renal, 
ovarian, lung and pancreatic cancers [7–9]. CD24 expression 
is also suggested to be a candidate marker for prognosis in 
breast cancer [10]. The CD44+/CD24− phenotype is among 
the most widely studied biomarkers for breast cancer stem 
cells (CSC), but the clinical impact of these reported CSC 
biomarkers remains controversial [11, 12]. CD44+/CD24-/low 
BC cells are reported to have tumor-initiating properties [12] 
and enhanced invasive activity [13]. Clinically, tumors with 
a higher fraction of CD44+/CD24- cells are more commonly 
found in patients with distant metastases [14] and associate 
with poor clinical outcome [15]. Recent studies indicate 
TNBCs also have higher representation of CD44+/CD24- 
cells [13, 15, 16], particularly among African American 
versus Caucasian women [17]. 
A cellular process that converts adherent epithelial 
cells into mesenchymal-like cells with the ability to 
migrate and invade adjacent tissues is termed epithelial-
mesenchymal transition (EMT), and the reverse process 
is designated mesenchymal-epithelial transition (MET) 
[18]. Recently, breast cancer cells were reported to transit 
between EMT and MET states and to play different 
biologic roles during metastasis [19]. The biomarker set 
CD44+/CD24−/low associates with more aggressive clinical-
pathological features in BC [20]. CD44+/CD24−/low cells 
generally display a mesenchymal phenotype [19, 21], 
while CD44+/CD24+/high cells tend to associate with more 
differentiated epithelial features [22]. 
Previous reports indicate that CD24 is involved in 
EMT-MET transitions in breast cancer cells. However, the 
association of a CD44+/CD24−/low population with the clinical 
outcome of patients with breast cancer and drug resistance, 
particularly to specific types of chemotherapeutics, is 
unclear [23]. Further, little is known about the regulatory 
mechanism for CD24 expression. Our earlier work indicated 
that treatment of BC cells with docetaxel induces the 
transition of BC cells from a CD44+/CD24−/low phenotype 
to a CD44+/CD24+/high phenotype  that is more resistant to 
docetaxel [24].  Later, work by Goldman et al. supported 
our findings on such antitumor drug-induced phenotypic 
plasticity [25, 26]. In contrast, some studies suggest that 
CD44+/CD24−/low cells are more resistant to chemotherapy, 
and that patients with tumors containing CD44+/CD24−/low 
cells have worse survival [27, 28]. These contrasting data 
highlight the complexities in defining the role of CD24 in 
TNBC responses to therapy. In this work, we focused on in 
vitro and in vivo studies of CD24 expression and potential 
underlying signaling pathways in TNBC drug resistance.
RESULTS
Docetaxel and doxorubicin regulate CD24 
expression in a different manner  
Drug-resistant cells are generally considered to be 
represented by cells that survive chemotherapy treatment. 
To study the relationship between CD24 functions 
and drug resistance, we treated cells with the two most 
commonly used drugs for TNBC, namely docetaxel and 
doxorubicin, and CD44/CD24 expression was tested 
before and after treatments. Overall, we investigated eight 
TNBC cell lines and compared these with six BC cell 
lines of other subtypes including three luminal and three 
HER2 positive cells, with representative results shown 
in Figure 1. In Supplementary Table 1, four of the eight 
TNBC cells had a main population of CD44+/CD24−/low 
cells. Of the three HER2+ cell lines tested, only JIMT-1 
had a large population of CD44+/CD24−/low, and the 
remaining were CD44+/CD24+/high. All luminal cell lines 
were CD44+/-/CD24+/high. The gating method and control 
information were described in Supplementary Figure 1.
After doxorubicin treatment, all CD44+/CD24−/low 
cell lines remained unchanged, while CD44+/CD24+/high 
cell lines showed decreased CD24 expression in the 
surviving cells (Figure 1; and data not shown). In contrast, 
cells responded differently after docetaxel treatment. All 
CD44+/CD24−/low cell lines had increased CD24 expression 
after docetaxel treatment (Figure 1; and data not shown). 
Both HCC1937 and HCC38 cells are CD44+/CD24+/high; 
however, HCC1937 cells showed no change in CD24 
expression, while HCC38 cells showed a decrease in 
CD24 expression after docetaxel treatment. Overall, 
our results suggest doxorubicin induces suppression 
of CD24 expression in CD44+/CD24+/high cells, while 
docetaxel may decrease, increase or have no effect on 
CD24 expression in different cell lines. Our results also 
indicate that sensitivities of TNBC cells to the two drugs 
associate with the CD24 phenotype of surviving cells 
after drug treatments. The decreased CD24 expression 
in HCC1937 cells after doxorubicin and increased CD24 
in HCC1806 cells after docetaxel as shown by FACS 
analyses were also confirmed by Western blot experiments 
(Supplementary Figure 2). Because CD24 expression 
in these cell lines changed rapidly after only a very 
short time of drug treatment before cell death occurred 
(Figure 5B, Supplementary Figure 2 and data not shown), 
the observed changes were less likely due to selective 
killing of particular cell populations.
To study whether expression of other important cancer 
biomarkers also change after chemotherapy treatment under 
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the same experimental conditions, we tested CD133 and 
CD49f markers using FACS and Aldehyde Dehydrogenase 
(ALDH) activity using an established Aldefluor assay. 
In comparison with CD24 expression after the two drug 
treatments, ALDH, CD133 and CD49f displayed different 
patterns of expression with no clear correlates or trends 
identified. (Supplementary Figure 3 and data not shown)
CD24 expression levels correlate with drug 
resistance
To test the hypothesis that CD24 expression 
affects drug resistance, we performed drug sensitivity 
assays of different cell lines treated with either 
docetaxel or doxorubicin. The results show that cell 
lines with predominant populations of CD44+/CD24+/high 
cells (HCC1187, MDA-MB-468 and HCC38) were 
more resistant to docetaxel, while cell lines with main 
populations of CD44+/CD24−/low cells (MDA-MB-231, 
MDA-MB-436 and HCC1806) were more resistant to 
doxorubicin (Figure 2A). Similar results were found 
using drug treatment in 3D culture assays (Figure 2B). 
In suspension conditions, the CD24+ cell line HCC1937 
became much more sensitive to doxorubicin (Figure 2C). 
Because CD24 expression can be altered by drug 
treatment, we next determined the drug sensitivity of those 
cells remaining after chemotherapy treatment. As shown in 
Figure 2D, 2E and 2F, the new CD44+/CD24−/low population 
induced by either docetaxel or doxorubicin was sorted out 
and found to be more resistant to doxorubicin compared 
with the CD44+/CD24+/high population of the same cell lines, 
whereas the new CD44+/CD24+/high population induced by 
docetaxel was more resistant to docetaxel compared with 
the CD44+/CD24−/low population. In HCC38 cells, docetaxel 
sensitivity was improved in newly-induced CD44+/CD24−/
low cells. These results suggest- that CD44+/CD24+/high cells 
were highly resistant to docetaxel, and CD44+/CD24−/
low cells were resistant to doxorubicin. Most of the cells 
became more resistant to the drugs after treatment in 
accord with the level of CD24 expression in surviving 
cells. Although HCC38 cells showed an induced population 
with decreased CD24 expression after docetaxel, the main 
population remained CD44+/CD24+/high, and continued to 
be docetaxel-resistant. These observations suggest that the 
drug resistance of tested cell lines is regulated by and/or 
associated with CD24 expression levels.
Targeting CD24 or its inhibitor NDRG2 
overcomes drug resistance 
To determine whether CD24 and potential CD24 
downstream signaling regulate drug resistance, we used 
specific shRNAs in vitro to suppress expression of CD24 
or the CD24 inhibitor NDRG2 [29]. After knockdown 
Figure 1: Docetaxel (DTX) induces CD24+/high to CD24−/low, or CD24−/low to CD24+/high transitions or no change of CD24 
expression in BC cell lines, while doxorubicin (DXR) only induces CD24+/high to CD24−/low transitions. (A) and (B) show 
Fluorescence-Activated Cell Sorting (FACS) results and the respective bar graphs. Error bars represent standard error of the mean (SEM). 
The p-values were calculated using an unpaired t test. *P < 0.05; ***P < 0.001. (A) The cells were treated with 6 µM docetaxel for 1 to 3 
days and then stained with CD24-PE and CD44-FITC for FACS analysis. HCC1806, HCC1937 and HCC38 are TNBC cell lines. JIMT-1 
is a HER2-overexpressing BC cell line. (B) HCC1806 and HCC1937 were treated with 4 µM doxorubicin for 1 to 3 days and then stained 
with CD24-Brilliant Violet 421 and CD44-FITC. (C) The summarized results of A and B.
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of CD24 in 3D culture, HCC1806 cells became more 
sensitive to docetaxel (Figure 3A). In contrast, cells 
with NDRG2 knockdown became more resistant to 
docetaxel and more sensitive to doxorubicin. Knockdown 
efficiency is shown in Supplementary Figure 2. Similar 
results were observed in another cell line, HCC1937, with 
knockdown of CD24 expression (Figure 3B). Conversely, 
overexpression of CD24 in HCC1806 leads to increased 
doxorubicin sensitivity (Figure 3C and 3D), a result 
consistent with enhancement of CD24 by suppression of 
the CD24 inhibitor NDRG2 as above. 
To confirm our in vitro data, in vivo studies were 
conducted in a tumor xenograft model. As shown in 
Figure 3E and 3F, TNBC HCC1806 tumor xenografts with 
NDRG2 knockdowns showed marked tumor reduction 
after doxorubicin treatment as compared to controls. On 
the other hand, tumors of HCC1806 cells with CD24 
knockdown demonstrated significant tumor reduction after 
docetaxel treatment as compared to controls (Figure 3G). 
Another TNBC line MDA-MB-231-with knockdown of 
CD24 also showed improved tumor response to docetaxel 
(Figure 3H) as predicted by the in vitro data. Statistical 
analysis of tumor shrinkage under different conditions as 
in Figure 3I demonstrate that inhibition of CD24 reduces 
docetaxel resistance, while increasing CD24 or suppressing 
CD24 inhibition improves doxorubicin sensitivity. 
These results suggest that targeting or modulating CD24 
expression may overcome drug resistance in TNBC. 
TGF-βR1 and Bcl-2 regulate CD24 expression 
and drug sensitivities
To investigate why docetaxel elicited variable 
CD24 expression in different BC cell lines, we focused 
on signaling pathways that could mediate observed 
phenomenon associated with CD24 expression. Of these, 
Bcl-2 was selected due to its reported involvement in 
paclitaxel resistance [30]. The CD44+/CD24−/low phenotype 
is shown to be related to EMT [21], and our results show 
that HCC1806 cells undergo partial MET after docetaxel 
treatment; and MDA-MB-468 cells undergo EMT after 
doxorubicin treatment (Supplementary Figure 4). Since 
Figure 2: CD24+/high TNBC cells are resistant to docetaxel (DTX) and CD24−/low TNBC cells are resistant to doxorubicin 
(DXR). (A) The drug sensitivity assay results of six TNBC cell lines dosed with either 25.6 µM docetaxel or 6.4 µM doxorubicin are shown. 
P-values were calculated with Two-way ANOVA. *P < 0.05; ***P < 0.001. (B) After seeding in matrigel for 4 days, cells were treated with 
0.6 µM docetaxel or 60 nM doxorubicin for 7 days. (C) HCC1937 cells were cultured under standard conditions or in ultralow-attachment 
plates for 2 days, then treated with 6 μΜ doxorubicin or 25.6 μΜ docetaxel for either 2- or 7 days. ***P < 0.001; ****P < 0.0001. (D) Work 
flow for experiments shown in (E) and (F). HCC1806 and HCC38 cells were treated with 25.6 µM docetaxel for 2-days. Treated cells were 
then sorted into CD44+/CD24+/high and CD44+/CD24−/low populations by FACS. Sorted populations were re-treated with 25.6 µM docetaxel, 
with cell viabilities determined after 2-days. MDA-MB-468 and HCC1937 cells underwent the same protocol except 6.4 µM doxorubicin 
was used. (E) and (F) P-values were calculated with unpaired t test. *P < 0.05; **P < 0.01. Error bars represent SEM. Scale bar, 200 µm. 
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TGF-β is one of the most important inducers of EMT 
and is a secreted protein [31],  TGF-βR1 is generally 
considered to reflect TGF-β downstream signaling [32]. 
Hence, TGF-βR1 was also selected for evaluation in 
the current study. We used gene microarrays to search 
for downstream signaling of Bcl-2 and TGF-β. The 
most differentially-expressed genes were listed in 
Supplementary Tables 2 and 3. Of interest, the ataxia-
telangiectasia mutated (ATM) pathway was markedly 
inhibited in HCC1806 cells by treatment with docetaxel 
(Figure 4B; Supplementary Table 4) and was therefore 
assessed further. Previous reports showed that increased 
expression of Twist and reduced expression of CD24 
contribute to EMT and to CSC self-renewal through 
activation of transcription 3 (STAT3)-dependent pathways 
in liver and breast cancers [33, 34]. As shown in Figure 4A, 
ATM signaling correlated positively with NDRG2 and 
STAT3 signaling as shown by simultaneous increase or 
decrease of p-ATM with p-NDRG2 and p-STAT3. Based 
on inhibitor treatments, our studies also show that ATM 
stimulates NDRG2, and increased NDRG2 negatively 
regulates ATM (Figure 5A and 5C). These results suggest 
ATM is upstream of NDRG2 and is inhibited by NDRG2 
via negative feedback loops. Using a similar approach, we 
demonstrated that both TGF-βR1 and Bcl-2 were upstream 
of ATM with TGF-βR1 being stimulatory and Bcl-2 being 
inhibitory to ATM. Both docetaxel and doxorubicin 
stimulated TGF-βR1 signaling. For Bcl-2, docetaxel 
stimulated, while doxorubicin was suppressive; and 
cyclophosphamide had no effect (Figure 6). Our results 
also show that Bcl-2 expression in both CD44+/CD24+/high 
cells -HCC1937 and HCC38- are very low. Further, 
HCC38 had higher levels of TGF-βR1 expression than 
HCC1937. Although CD44+/CD24−/low cells (HCC1806 
and MDA-MB-231) had high levels of TGF-βR1 
activity, Bcl-2 activities in these cells were even more 
elevated thereby serving as a dominant signaling function 
(Figure 6B). The expression of autophagy marker-
Figure 3: Targeting CD24 and its inhibitor gene NDRG2 by shRNAs improved chemotherapy sensitivity in vitro 
and in vivo. (A, B, C and D) After seeding in matrigel for 5-days, HCC1806 cells were treated with 20 nM docetaxel (DTX) or 1.5 µM 
doxorubicin (DXR) for 4-days. HCC1937 cells were treated with 0.6 µM docetaxel. P-values of the compared groups were calculated 
using unpaired t-tests for cell total area. (E) These data show the working scheme for treatments used in tumor xenograft experiments. 
(F, G, H) These data show results of experiments with five tumors in each treatment group. (I) These data show statistical analyses of tumor 
shrinkage in the three pairs of experiments. P-values of each paired group were calculated with paired sample t-tests. *P < 0.05; **P < 0.01; 
***P < 0.001. Error bars represent SEM. Scale bar, 200 µm. 
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LC3B was next tested in CD24 knockdown and NDRG2 
knockdown cell lines (Figure 6E). The results show that 
CD24 knockdown elevates LC3B expression and NDRG2 
knockdown diminishes LC3B levels in the tested cells and 
suggest that CD24 might affect the autophagy process in 
these cells. 
Taken together, our results indicate that interactions 
between Bcl-2/TGF-βR1 signaling regulate CD24-
mediated drug resistance (Figure 6F). ATM stimulates 
NDRG2 activity which negatively regulates CD24. 
Doxorubicin may inhibit Bcl-2 and leave TGF-βR1 
signaling unopposed, which leads to ATM stimulation and 
reduction of CD24 expression. In contrast, docetaxel may 
stimulate both TGF-βR1 and Bcl-2 signaling. Whether 
docetaxel stimulates or inhibits ATM appears to depend 
on the balance between activities of TGF-βR1 and Bcl-2 
signaling. When Bcl-2 signaling dominates over TGF-βR1 
signaling, ATM is inhibited, and vice-versa. 
Molecular findings on the involvement of these 
key factors in drug resistance were also confirmed at 
the cellular level (Figure 5B; Supplementary Figures 5 
and 6). Briefly, knockdown of Bcl-2 elicits a decrease 
of CD24 expression in HCC1937 and HCC1806 
cells; knockdown of TGF-βR1 increases CD24 only 
in HCC1806 but not in HCC 1937 because of its high 
basal level. Knockdown of Bcl-2 also stimulates self-
renewal of HCC1806 cells in suspension culture; while 
knockdown of TGF-βR1 or ATM kinase reduces self-
renewal in the same cells. Also knockdown of Bcl-2 
induces differentiation (3D sphere-like structures) 
of HCC1806 cells while knockdown of TGF-βR1 or 
ATM kinase decreases differentiation of these cells in 
3D culture. The effects of TGF-βR1, Bcl-2 and ATM 
on cell drug sensitivities were confirmed using their 
corresponding inhibitors in HCC1806 and HCC1937 
cells (Supplementary Figure 6E and 6F).  
Figure 4: ATM signaling regulated by chemotherapy drugs. (A) Results from three cell lines, HCC1937, HCC1806 and HCC38, 
treated with 6.4 µM docetaxel (DTX), 4 µM doxorubicin (DXR) or 5 µM STAT3 inhibitor VII. Levels of phospho-ATM, -NDRG2 and 
-STAT3 showed congruent changes following a similar trend: p-NDRG2 and p-STAT3 were increased when p-ATM was upregulated; 
p-NDRG2 and p-STAT3 were decreased when p-ATM was suppressed. (B) Gene microarray data show that expression of genes in the ATM 
pathway was dramatically reduced after 6 h of 4 µM docetaxel treatment. The genes changed ≥ 2 folds and P < 0.05. 
Oncotarget38300www.impactjournals.com/oncotarget
Figure 5: Bcl-2, TGF-βR1 and ATM signaling assessed by Western blot and FACS in selected TNBC cell lines. (A) Cells 
were treated with 10 µM ATM inhibitor KU60019. (B) FACS results showed that 10 µM ATM inhibitor increased CD24 expression in 
MDA-MB-231 cells; and 4 µM doxorubicin reduced CD24 expression. (C) Selected cells were transfected with control vector, CD24 
shRNA or NDRG2 shRNA. Knockdown of NDRG2 caused dramatic p-ATM increase in HCC1806 and MDA231 cells (D) The cells 
were treated with docetaxel 6.4 µM or doxorubicin 4 µM. Both docetaxel and doxorubicin increased p-TGF-βR1 in the three cell lines. 
Doxorubicin reduced p-Bcl-2 in HCC1937 and docetaxel elevated p-Bcl-2 in HCC1806 and HCC38.
Figure 6: Interactions between Bcl-2, TGF-βR1 and ATM signaling in TNBC cells treated with either docetaxel (DTX) 
or doxorubicin (DRX). (A) and (B) Western blot results. Docetaxel: 6.4 µM; doxorubicin: 4 µM; cyclophosphamide: 2 µM. The 
results showed that doxorubicin reduced p-Bcl-2 in HCC1937 and HCC1806 and docetaxel increased p-Bcl-2 in the same cell lines. 
Cyclophosphamide had no significant effect on p-Bcl-2 in the two cell lines. HCC38 had a relatively higher basal level of TGF-βR1 
compared to HCC1937. The bands of p-Bcl-2, Bcl-2 and β-actin in HCC1806 treated with DTX and HCC1937 treated with DXR have been 
shown in Figure 5. They were shown here again for a different comparison. (C) Cells were treated with 5 µM Bcl-2 inhibitor ABT-737. The 
results showed that Bcl-2 inhibitor stimulated p-TGF-βR1 and p-ATM, suggesting that Bcl-2 is an inhibitor of TGF-βR1 and ATM in the 
three cell lines. (D) Cells were treated with 5 µM TGF-βR1 inhibitor LY 364947. The results showed that TGF-βR1 inhibitor suppressed 
p-ATM and TGF-βR1 is stimulatory to p-ATM. (E) The Western blot results of autophagy marker-LC3B. The results showed that CD24 
knockdown increased LC3B expression and NDRG2 knockdown eliminated LC3B expression. (F) Proposed diagram to summarize 
contrasting effects of doxorubicin and docetaxel on critical TNBC cell signaling pathways.   
Oncotarget38301www.impactjournals.com/oncotarget
CD24 is a potential biomarker for selection of 
chemotherapy regimens
We next explored clinical significance of CD24 
expression in archival patient specimens. For survival 
analysis, we selected 94 cases of TNBC patients who were 
treated with adjuvant chemotherapy. As a group, patients 
with CD24−/low tumors had significantly better survival 
than those with CD24+/high tumors (Figure 7A). Only 
21 patients in the study cohort received anthracycline 
(doxorubicin) without taxanes (either paclitaxel or 
docetaxel). The better overall survival rate and disease free 
survival rate of patients with CD24–/low tumors treated with 
taxane-based regimens was even more evidenced after 
excluding patients who received only doxorubicin (Figure 
7B–7F). The relationship between CD24 expression and 
TNBC recurrence was further supported by studying 
a separate cohort of 9 cases shown in Supplementary 
Table 5. The results showed that all patients with high 
CD24 expression (2+ or 3+) before or after neoadjuvant 
treatment developed recurrent disease (mean time to 
recurrence 13.7 months) and all patients with low CD24 
expression (0 or 1+) had no recurrent disease (mean 
follow up 47.5 months). Patient #5 whose tumor was 1+ 
before neoadjuvant treatment but increased to 2+ after 
taxane-based neoadjuvant treatment, later developed 
recurrent disease. Clinicopathological characteristics of 
patients whose tumors were included in the TNBC TMA 
are addressed in Supplementary Table 6.  
DISCUSSION
It is commonly reported that negative/low 
expression of CD24 is a characteristic biomarker of 
promoting tumor initiation and progression [12]. Results 
presented here demonstrated a unique mechanism of 
differential resistance to chemotherapeutics determined 
by CD24 and regulated in part by the balance of TGF-
βR1 and Bcl-2 signaling. Our findings on tumor 
specimens from the clinic further supported that CD24 
may be an important prognostic factor for TNBC patients 
who receive taxane-based treatment. In accord with our 
hypothesis, Chekhun et al. reported that TNBC patients 
with CD24−/low tumors treated with doxorubicin-based 
chemotherapy regimens CAF (cyclophosphamide, 
doxorubicin and fluorouracil) or AC (doxorubicin and 
cyclophosphamide) had significantly worse survival 
rates than those patients with CD24+/high tumors [28]. In 
addition, Lee et al. reported that patients treated with 
an AC regimen had a significantly shorter disease-free 
interval [35]. Independent preclinical findings also show 
that CD44+/CD24–/low BC cell subpopulations exhibit 
resistance to anthracycline drugs [36, 37]. These several 
clinical and preclinical reports support our hypothesis 
that CD24–/low BC cells are resistant to anthracycline 
treatment.
Our data also suggest that targeting CD24 and 
its regulatory pathways can reduce drug resistance in 
BC cells. When administering docetaxel to CD24−/low 
Figure 7: High expression of CD24 in archival tumor specimens from TNBC patients treated with taxane-based 
chemotherapy associate with poor prognosis. Kaplan-Meier survival curves are shown in relation to CD24 expression in archival 
tumor specimens represented in a TNBC Microarray (TMA). (A) Overall survival analysis of all patients who received either doxorubicin- 
or taxane-based treatments. (B), (C) Data show that the survival analysis was limited to only patients who received taxane-based regimens. 
(B, overall survival analysis; C, disease-free survival analysis). (D) Representative CD24 IHC staining of TNBC TMA is shown. The 
specificity of CD24 staining was confirmed using TNBC cells stained with the same antibodies and IHC reagent kit (data not shown). 
(E, F) Representative CD24 staining of tumor samples from 4 of the 9 patients noted in Supplementary Table 5 is shown. Scale bar, 200 µm. 
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tumors, adding agent(s) to block a phenotype switch 
from CD24−/low to CD24+/high may prevent development 
of adaptive resistance to docetaxel. Similarly, applying 
doxorubicin to CD24+/high tumors, while blocking the 
transition from CD24+/high to CD24−/low phenotype, may 
improve doxorubicin sensitivity of treated cells. Future 
investigations in modulation of specific TNBC signaling 
pathways involved in regulating CD24 may lead to new 
therapeutic approaches. Our study further suggests that 
sequential administration of doxorubicin and taxane 
drugs may be more effective to improve TNBC treatment. 
We show that treating with docetaxel in CD24−/low cells 
first, followed by doxorubicin, significantly improves the 
overall cytotoxic effect, whereas the reverse sequence 
of these drugs in the same cells results in a significantly 
reduced cytotoxicity (Supplementary Figure 6C). Of note, 
in CD24+/high TNBC cells, the reverse sequence of drug 
administration (e.g., doxorubicin followed by docetaxel) 
yields better results (Supplementary Figure 6D). 
The EMT process facilitates tumor cell migration 
through basement membrane, invasion into adjacent 
tissues, and penetration into the circulation [38, 39]. 
However, distant metastases from these tumors often show 
more differentiation with increased expression of luminal 
epithelial marker CD24 [40]. In addition, TNBCs with 
high CD24 expression associate with worse overall patient 
survival and shorter distant metastasis-free survival than 
tumors with low CD24 [23]. These observation may be 
related to our finding of high recurrence rates in patients 
with CD24+ TNBC who are treated with taxane-based 
regimens, but further investigation is needed to clarify the 
involvement of CD24 in metastasis as well as regulation 
of the host immune response [23, 41]. 
It is well-established that a major reason for 
treatment failure in patients with TNBC is development of 
resistance to chemotherapies which leads to early relapse 
or distant spread leading to patient death. Emerging 
reports suggest that metastatic tumor cells may evade 
cell death in part by the induction of autophagy, a tightly-
regulated process involving the degradation of excessive, 
damaged or unnecessary proteins or injured organelles 
by lysosomal pathways to ensure the maintenance of 
cell viability [42, 43]. Several studies now suggest that 
autophagy plays an important role in cancer and in drug 
resistance [43–47]. Autophagy may promote cell survival 
in cancer cells treated with chemotherapy or lead to 
autophagic tumor cell death depending on the duration or 
extent of the induction of this process. As noted in our 
work, the potential relationship between autophagy and 
chemotherapeutic drugs is being explored in the context of 
the regulation of autophagy by CD24 which is modulated, 
in turn, by Bcl-2, ATM and associated signaling pathways 
[46, 47]. Our studies using antisense tools to up-regulate 
and down-regulate CD24 in breast cancer cells suggest a 
relationship between CD24 expression and biomarkers 
of autophagy in vitro. Whether autophagy is largely 
pro-tumorigenic or anti-tumorigenic is unclear, but 
independent efforts are underway to investigate autophagy 
as a potential target of antitumor drugs and the targeting 
of autophagy as a therapeutic strategy to modulate drug 
resistance [43–47].  This work helps to contribute to that 
effort [27, 45–47]. Further, the induction of autophagy in 
cancer cells is also associated with inhibition of cell lysis 
by cytotoxic T-lymphocytes, suggesting that regulation of 
autophagy may be important in the future development of 
immunotherapeutic strategies to block immune escape by 
TNBC [48].   
Our findings to date suggest that regulation of CD24 
expression in tumor cells is due in part to the balance of 
Bcl-2 and TGF-βR1 signaling via downstream activities 
of ATM and NDRG2, a notable tumor suppressor gene 
product that regulates CD24 expression to decrease the 
metastatic potential of breast cancer cells. Independent 
reports concur with several aspects of our findings such as 
the induction of ATM by doxorubicin in cardiac myocytes 
[49] and TGFβ- induced apoptosis via ATM in epithelial 
cells [50]. In addition, docetaxel is reported to enhance 
B1/Cdk1-mediated phosphorylation of Bcl-2 [51], while 
Hao et al. report that down-regulation of Bcl-2 enhances 
the sensitivity of polyploid cells to docetaxel [52].  How 
the downstream signaling of CD24 causes the change in 
sensitivity of tumor cells to taxane versus anthracylines 
remains to be answered. Since autophagy was previously 
reported to related closely to the CD44+/CD24- status in 
TNBC cells [53], we assessed the autophagy biomarker 
LC3B in cells with selective knockdown of CD24 
expression or in those with suppression of the CD24 
inhibitor NDRG2. The results show that knockdown of 
CD24 led to a significant increase of autophagy marker 
LC3B, while knockdown of NDRG2 reduced LC3B in 
TNBC cell lines HCC1806 and HCC1937 (see Figure 6E). 
Importantly, independent reports also show that enhanced 
autophagy in BT-549 and MDA-MB-231 cells helped to 
promote tumor cell survival after doxorubicin treatment 
[54]. Also consistent with our findings was the report 
that diminished levels of autophagy-initiating genes 
caused MCF-7 and SKBR-3 cells to develop resistance 
to taxane therapy [55].  Taken together with independent 
research, this evidence suggests the hypothesis that 
selective changes in CD24 expression may regulate the 
drug sensitivities of tumor cells in part through modulation 
of cellular autophagy status. Further, these data on the 
identification of specific downstream pathways that 
regulate CD24 may help to explain prior controversial 
findings regarding the role of CD24 in drug resistance and 
phenotypic plasticity in TNBC cells. 
To further understand the mechanism of CD24-
regulated drug sensitivity in TNBC, we also assessed other 
cancer stem cell markers, such as ALDH, CD133 and 
CD49f.  Interestingly, changes in the patterns of expression 
of these other cancer stem cell markers were different 
from those of CD24 expression. There was no clear trend 
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of changes observed among different cell lines after the 
two drug treatments. Thus, more studies are needed in the 
future to define the potential relationships of other cancer 
stem cell markers with drug resistance in breast cancers. 
In summary, the current data suggest that CD24 is 
a promising biomarker candidate to guide chemotherapy 
selection in the clinic, particularly in choosing between 
commonly-used TNBC therapeutics such as docetaxel and 
doxorubicin. This strategy may potentially be applied in 
future clinical trials and, if successful, could help to improve 
chemotherapy selection for the benefit of TNBC patients.
MATERIALS AND METHODS
Cell lines and cell culture
All cell lines except those noted below were 
obtained from the American Type Culture Collection 
(Manassas, VA, U.S.A.) and were used within six months 
of receipt for experimentation. JIMT-1, HCC1419 and 
SKBR3 cells were provided by Dr. Dennis Slamon 
(UCLA) and were authenticated in his laboratory by 
confirmation of genomic DNA, in comparison with 
the ATCC database. Experiments using these cell lines 
were also done within six months of receipt. Cells were 
maintained in Dulbecco’s Minimal Essential Medium 
(Invitrogen, Carlsbad, CA, U.S.A.) or RPMI 1640 
(Invitrogen) with 10% heat-inactivated Fetal Bovine 
Serum (FBS; Fisher Scientific, Pittsburgh, PA, U.S.A.), 
100 units/mL penicillin, and 100 µg/mL streptomycin, 
at 37°C in 5% CO2. To assay self-renewal capacity, cells 
were seeded in Corning Ultra-Low Attachment 96-well 
Plates (Fisher Scientific) at 10,000 cells/well and cultured 
two days [56]. For 3D culture, cells were seeded at 10,000 
cells/well in 96-well plates and grown in 40 µl Matrigel 
using established methods (Fisher Scientific) [57]. 
Transfection
The siRNA against Bcl-2 (Cat No. AM16708), 
TGF-βR1 siRNA (Cat No. AM51331), and control 
siRNA (Cat No. AM4611) were from Invitrogen. 
Transfection of siRNAs was done with Lipofectamine® 
RNAiMAX Transfection Reagent (Invitrogen) according 
to manufacturer’s instructions. Cells were collected for 
analysis at 48 h post-transfection.
For plasmid transfections, HCC1806 cells were 
transfected with human CD24 with pCMV6-AC-GFP 
vector (Cat No. RG209542) or negative control (Cat 
No. PS100010) (OriGene Technologies, Rockville, MD, 
U.S.A.) using Lipofectamine 2000 (Invitrogen) according 
to manufacturer’s instructions. Cells were sorted for GFP-
positive markers 2–5 times to select transfected cells with 
stable staining. 
To suppress CD24 and NDRG2 expression, 
HCC1937, HCC1806 and MDA-MB-231 cells were 
transfected with either CD24 shRNA (Cat No. TF321436), 
NDRG2 shRNA (Cat No. TF303005) or negative control 
vector (OriGene Technologies) using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instructions. 
Cells were sorted for RFP-positivity 2 -5 times to obtain 
transfected cells with stable staining.
Fluorescence-activated cell sorting (FACS) and 
aldefluor assay
CD24-PE (ML5 clone) and CD44-FITC antibodies 
were from BD Biosciences (San Jose, CA, U.S.A.). To 
evade the autofluorescence of doxorubicin, Brilliant Violet 
421™ anti-human CD24 Antibody (ML5 clone, BioLegend, 
San Diego, CA, U.S.A.) was used for doxorubicin-treated 
cells and the related control cells. For each sample, 
triplicates of 2 × 105 cells/well were cultured in 6-well 
culture plates and treated with selected reagents. After 
treatment, cells were detached from plates using StemPro® 
Accutase® Cell Dissociation Reagent (Invitrogen), followed 
by centrifugation and re-suspension in 100 µl cold FACS 
buffer I (growth medium/PBS, 1:1, vol/vol). Cells were 
then transferred to 96-well U-bottom plates (Genesee 
Scientific, San Diego, CA, U.S.A.). Cells were incubated 
with antibodies on ice 30 min, spun down and washed 
3-times with FACS buffer I. Cells were then re-suspended 
with FACS buffer II (5% FBS in PBS with 2 mM EDTA) 
and submitted for analysis or cell sorting. The same numbers 
of cells were analyzed in the same set of experiments. 
ALDH activity was tested using an ALDEFLUOR™ Kit 
(STEMCELL Technologies Inc., Vancouver, BC, Canada) 
according to the manufacturer’s instructions. Briefly, single 
cells were suspended in ALDH assay buffer containing 
ALDH substrate BODIPY-aminoacetaldehyde (BAAA) 
and incubated at 37°C for 40 min. The specific ALDH 
inhibitor diethylaminobenzaldehyde at 50 mM was used 
as a negative control. Stained cells were analyzed by flow 
cytometry.  Results were analyzed by FlowJo 7.6 (FlowJo 
LLC, Ashland, OR, U.S.A.).   
Drug sensitivity assay
Cells were seeded at a density of 10,000/well 
in 96-well plates (Fisher Scientific) and then treated 
with selected drugs or DMSO negative control for 
48 h. Docetaxel, doxorubicin hydrochloride and 
cyclophosphamide monohydrate were from Sigma-
Aldrich (St. Louis, MO, U.S.A.). At the end of treatment, 
cell viabilities were determined by using CellTiter-Glo 
Luminescent Cell Viability Assays (Promega, Madison, 
WI, U.S.A.). All experiments were performed in triplicate. 
Immunofluorescence staining and microscopy
Mouse anti-E-cadherin antibody was from 
Invitrogen, and mouse anti-vimentin antibody was from 
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Abcam (Cambridge, MA, U.S.A.). Secondary antibodies 
were from Invitrogen. Approximately 2.5 × 104 cells were 
seeded on a 4-well Lab-TekII Chamber Slide and treated 
with DMSO or chemotherapeutics. After 48 h, cells were 
washed twice with PBS and incubated with blocking 
solution (10% goat serum in PBS). Following three washes 
with PBS, cells were incubated with primary antibodies at 
4°C for 100 min and were followed by 3- washes with PBS 
for 15 min. Cells were finally incubated with secondary 
color-conjugated antibodies (Invitrogen) for 100 min. 
Slides were washed thoroughly with PBS and mounted 
with ProLong® Gold Antifade Reagent (Thermo Fisher 
Scientific Inc.). All matched samples were photographed 
(control and test) using a Nikon  fluorescence microscope 
with identical exposure times. 
Quantitative RT-PCR
Quantitative real-time PCR was performed using 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
as a housekeeping reference and EXPRESS One-Step 
SYBR® GreenER™ (Thermo Fisher Scientific Inc.) 
on an Applied Biosystems 7500 Fast Real-Time PCR 
system (Thermo Fisher Scientific Inc.), using the standard 
protocol as recommended by the manufacturer. The 
condition used for cDNA synthesis was 50°C for 5 min, 
and the condition for elongation was 60°C for 1 min. The 













HCC1806 cells were treated with DMSO or 4 µM 
docetaxel for 6 h. After treatment, mRNAs of samples 
were prepared and submitted for Affymetrix Human 
Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, 
CA, U.S.A.) analysis in duplicate. Total RNA was 
extracted using TRIzol Reagent (Life Technologies, NY, 
U.S.A.) followed by Qiagen column purification (Qiagen, 
Valencia, CA, U.S.A.). The array hybridizations were 
performed by the UCLA Clinical Microarray Core Service 
following standard Affymetrix GeneChip Expression 
Analysis protocols. Acquisition of the array image was 
undertaken using Affymetrix GeneChip Command 
Console 4.0 (Affymetrix). Subsequent raw data were 
analyzed using Partek Genomics Suite 6.4 (Partek, St. 
Louis, Missouri, U.S.A.) and Affymetrix Transcriptome 
Analysis Console (Affymetrix, Version 2.0.0.9). We 
used the RMA algorithm for data normalization. Global 
functional analyses, network analyses and canonical 
pathway analyses were performed using Ingenuity 
Pathway Analysis (Ingenuity® Systems, www.ingenuity.
com). Data obtained from the microarray are deposited at 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE70690).
Western immunoblot methods, inhibitors and 
antibodies 
Cells were lysed in RIPA buffer supplemented 
with Phosphatase Inhibitor Cocktail Tablets and Protease 
Inhibitor Cocktail Tablets (Roche, Basel, Switzerland). 
For signaling analyses, cells seeded onto 6-well 
plates at 2 × 105 cells/well were treated with selected 
chemotherapeutics or inhibitors. TGF-βR1 inhibitor 
LY364947 was purchased from Cayman Chemical (Ann 
Arbor, Michigan, U.S.A.) and LY2157299 was from 
Selleckchem (Houston, TX, U.S.A.). Stat3 Inhibitor 
VII was from EMD Millipore (Billerica, MA, U.S.A.). 
ATM kinase inhibitor KU60019 was from Santa Cruz 
Biotechnology (Dallas, TX, U.S.A.). Bcl-2 inhibitor 
ABT-737 was from Selleckchem and G3139 was 
from Alpha DNA (Montreal, Quebec, Canada). These 
inhibitors were selected based on prior reports [59–62]. 
Sheep anti-NDRG2 phospho-Thr348 antibody was from 
Kinasource Limited (Dundee, Tayside, UK). Rabbit anti-
TGF-βR1 phospho S165 antibody was from Abcam. 
Rabbit anti-TGF-βR1 antibody, mouse anti-Bcl-2 antibody 
and mouse anti-Stat3 antibody were purchased from EMD 
Millipore. Mouse anti-human CD24 antibody (ML5 clone) 
and mouse anti-Stat3 Phospho (Tyr705) antibody were 
from BioLegend. Rabbit anti-NDRG2 antibody, rabbit 
anti-ATM antibody, mouse anti-Phospho-ATM (Ser1981) 
antibody, rabbit anti-Phospho-Bcl-2 (Ser70) antibody, 
anti-mouse IgG HRP-linked antibody and anti-rabbit IgG 
HRP-linked antibody were from Cell Signaling (Danvers, 
MA, U.S.A.). Donkey anti-Sheep IgG HRP-linked 
antibody was purchased from Invitrogen. Mouse anti-β-
actin antibody was from Sigma-Aldrich. Western blotting 
was done by separating equal amounts of proteins on 
SDS-PAGE and transferring samples onto nitrocellulose 
membranes prior to detection with indicated antibodies 
and SuperSignal West Pico Chemiluminescent Substrate 
and SuperSignal ELISA Femto Maximum Sensitivity 
Substrate (Fisher Scientific). β-actin was used as loading 
control. All experiments were performed at least twice. 
Mice and tumor xenograft experiments 
CBySmn.CB17-Prkdcscid/J 4- to 6-week-old female 
mice from The Jackson Laboratory (Bar Harbor, Maine, 
U.S.A.) were used in this study. The protocol was approved 
by UCLA’s Office of Animal Research Oversight (OARO) 
and the Institutional Animal Care and Use Committee 
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(IACUC), with procedures performed under supervision 
of UCLA’s Division of Laboratory Animal Medicine. Mice 
were housed in aseptic conditions in micro-isolator cages 
and were provided sterile food and water. 
Tumor cells were adjusted to a concentration of 
3 × 106 in 50 µl growth medium mixed with 50 µl matrigel. 
100 µl cell suspension was injected subcutaneously using 
a 25G sterile needle in the 4th mammary fat pad of each 
mouse under isoflurane anesthesia. Mice were then assigned 
based on tumor size after one week and divided into 6 
treatment groups with 5 mice/ group. Groups 1 and 2 were 
injected with HCC1806 cells transfected with vector control 
or NDRG2 shRNA. Groups 3 and 4 were injected with 
HCC1806 cells transfected with vector control or CD24 
shRNA. Groups 5 and 6 were injected with MDA-MB-231 
cells transfected with vector control or CD24 shRNA. 
Chemotherapy drugs were administered intraperitoneally 
on days 9 and 14 after tumor inoculation. Groups 1 and 2 
were treated with doxorubicin at 0.06 mg/120 µl/mouse and 
Groups 3 to 6 were treated with docetaxel at 0.28 mg/120 µl/ 
mouse. Tumors were measured at specified time 
points, with tumor volume calculated as follows: tumor 
volume = ½(width)² × (length). At the end of experiments, 
mice were euthanized by CO2 inhalation at 21 or 23 days 
after tumor injection, and tumors were harvested. 
Tissue microarrays (TMA), regular tumor 
tissue samples and corresponding clinical and 
pathological database
A cohort of 94 TNBC specimens from the UCLA 
Pathology Tumor Bank were used for tissue microarray 
construction under IRB-approved protocols (#11-003372). 
Clinical-pathological characteristics, treatments, and 
outcomes of the 94 patients were abstracted from an IRB-
approved retrospective database at the Revlon/UCLA 
Breast Center (#11-000826).
To further confirm the relationship between CD24 
expression and TNBC recurrence, we studied additional 
9 patients treated with taxane-based chemotherapy 
(neoadjuvant or/and adjuvant). Tumor samples from these 
9 cases were stained for CD24 by a laboratory researcher 
and read by a breast pathologist. Both investigators were 
blinded for clinical information. The standard IHC staining 
protocol is described below. 
Immunohistochemical analysis of CD24
After antigen retrieval in Dako Cytomation Target 
Retrieval Solution (DAKO, Carpinteria, CA, U.S.A.), 
slides were stained with primary antibodies (CD24, 
ML5 clone) and biotin-conjugated secondary antibodies, 
followed by incubation with Streptavidin Peroxidasee 
and Substrate-Chromogen solution (DAKO). Blinded 
immunohistochemical scoring was performed by a breast 
pathologist. CD24 staining was detected at the membrane 
and cytoplasm of tumor cells, and scoring was done as 
follows: 0, 0–10% of positive tumor cells; 1+, 10–25% of 
positive tumor cells; 2+, 25–50% of positive tumor cells; 
3+, more than 50% of positive tumor cells. The cases 
were divided into negative/low, if scored 0 or 1+, and 
significantly positive cases, when scored as 3+. Patients 
initially presenting with metastases of any type, local 
or regional recurrence, or another primary cancer were 
excluded (n = 10) from the survival analysis. 
Statistics
All tests were two-sided, and p-values < 0.05 were 
considered statistically significant. Statistical calculations 
were done with Graphpad Prism 6 (GraphPad Software, 
Inc., La Jolla, U.S.A.) and Excel (Microsoft, Redmond, 
WA, U.S.A.). Individual statistical methods are described 
in appropriate figure legends and other methods sections.
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